Use of optiflow THRIVE high-flow nasal oxygen system versus a non-rebreather oxygen delivery device in patients with increased risk of airway obstruction in interventional radiology procedures: a randomized pilot study Authors: Gang Zheng, Mike Hernandez, Carin A. Hagberg Published: 2026 ABSTRACT BackgroundThe configuration of interventional radiology (IR) suites often limits simultaneous access to the patient’s airway and anesthesia equipment. This constraint may lead to suboptimal sedation in patients at increased risk of airway obstruction due to patient safety concerns. We conducted a randomized pilot trial to evaluate whether high-flow nasal oxygen (HFNO; F&P Optiflow™) reduces hypoxic events compared with a standard non-rebreather mask in this high-risk population undergoing deep sedation.MethodsPatients at increased risk of airway obstruction or hypoxia during deep sedation were randomized to receive 100% oxygen via HFNO at 70 L/min (HFNO group) or via non-rebreather mask at 8 L/min (standard-of-care [SoC] group). All patients received continuous intravenous propofol to achieve unconsciousness while maintaining spontaneous ventilation. The primary endpoint was total length of desaturation episodes [ToLDE], in minutes, defined as oxygen saturation [SpO2] ≤92%. Secondary outcomes included the number of desaturation episodes, bispectral index (BIS) excursions (defined as episodes of BIS value ≥ 61), postanesthesia care unit (PACU) length of stay, and patient-reported symptoms.ResultsA total of 101 patients were analyzed (HFNO group: n = 50; SoC group: n = 51). Mean ToLDE time was 0.34 min (median, 0; range 0–6.5 min) in the HFNO group and 0.97 min (median, 0; range 0–19.8 min) in the SoC group (P = 0.158). Desaturation occurred in 14% of HFNO patients vs. 26% of SoC patients (P = 0.212). The median number of BIS excursions was significantly higher in the SoC group (4; range, 0–19) than the HFNO group (2; range, 0–15; P = 0.005). Median PACU stay was shorter in the HFNO group (20 min; range, 0–60) vs. in the SOC group (26 min; range, 5–60) (P = 0.076). Patient-reported symptoms were less frequent and less severe in the HFNO group (12% vs. 16%).ConclusionsHFNO did not significantly reduce hypoxic events compared with a standard non-rebreather oxygen delivery device in patients at increased risk of airway obstruction during deep intravenous sedation. However, HFNO was associated with improved sedation stability and patient experience, supporting further investigation in larger studies.Trial registrationClinicalTrials.gov ID: NCT04171037; Date of original registration: November 19, 2019; This study was retrospectively registered. Study principal investigator: Gang Zheng; This manuscript adheres to the applicable Consolidated Standards of Reporting Trials (CONSORT) guidelines. Introduction Patients at increased risk of airway obstruction who are positioned supine during interventional radiology procedure are particularly vulnerable to hypoxic events, especially under deep sedation. In addition, the physical layout of IR suites often limits simultaneous access to both the patient’s airway and the anesthesia machine. These constraints may lead to clinicians to administer lighter-than-optimal sedation due to airway safety concerns, resulting in patient discomfort, awareness, and procedural pain. Clinical reports have suggested that high-flow nasal oxygen (HFNO) prolongs safe apneic oxygenation time and reduces hypoxic events [1–3]. This randomized pilot study was designed to evaluate whether HFNO reduces hypoxic episodes and improves patient experience compared with a standard non-rebreather mask during anesthesia in patients at increased risk of airway obstruction. We hypothesized that using HFNO in patients with increased risk of airway obstruction would be superior to using a standard non-rebreather mask to deliver a flow of 100% oxygen in reducing desaturation episodes during deep sedation if airway obstruction occurs. Methods Ethical approvals This study adhered to the Declaration of Helsinki and was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center (IRB2019-0348) and was registered in ClinicalTrials.gov (NCT04171037) and in the Clinical Trials Reporting Program database (NCI-2019-07291). All patients provided and signed an informed consent. Led by principal investigator Gang Zheng and supported by Fisher & Paykel Healthcare, this study was a prospective randomized controlled pilot study. This manuscript adheres to the applicable Consolidated Standards of Reporting Trials (CONSORT) guidelines. Study overview Patients were randomized in a 1:1 ratio by the Clinical Oncology Research System (MD Anderson copyright 2000–2007) to receive either HFNO or the standard of care (SoC). Random block sizes were used to ensure numerical balance between study arms. Patients in the HFNO group received the delivery of100% oxygen via an Optiflow system (AA030 Optiflow Trace, Fisher & Paykel Healthcare, New Zealand), and patients in the SoC group received a flow of 100% oxygen delivery via a non-rebreather face mask (Medline HUD1061, IL USA). A focused airway history and bedside airway assessment were conducted, and informed consent was obtained in the preoperative area. All patients underwent standardized airway assessments preoperatively. During the procedure, all patients received total intravenous anesthesia by a continuous intravenous propofol infusion to achieve a state of unconscious while maintaining spontaneous ventilation without initial airway instrumentation. If a patient appeared to have airway obstruction based on the anesthesia provider’s judgement, the airway was transiently supported by head-tilt, chin-lift, jaw thrust maneuvers, or insertion of an oral or nasal artificial airway. For patients in the HFNO group, the oxygen flow rate was initiated at 50 L/min and increased to 70 L/min after the initiation of a propofol infusion and was maintained at 70 L/min until the end of the procedure. For patients in the SoC group, the oxygen flow rate was maintained at 8 L/min throughout the entire procedure. Patients’ oxygen saturation (SpO2) levels were continuously monitored and manually recorded. The bispectral index (BIS) was used to monitor the level of sedation in both groups. BIS readings of 40–60 denoted an adequate condition of deep sedation. Postoperative assessments with a standard checklist were performed in the postanesthesia care unit (PACU) once patients were fully awake. Patients reported if they experienced any awareness during the procedure, sore jaw or tongue, dysphagia, or dysphonia. As part of standard postoperative assessment in PACU, self-reported symptoms were recorded for up to 30 min after admission in the PACU, and the length of the PACU stay in minutes was recorded. Study endpoints The primary endpoint was the total length of desaturation episodes [ToLDE], in minutes, that a patient experienced during a 60-minute observation window starting from the initiation of the propofol infusion. A desaturation episode was defined as a drop in SpO2 to 92% or lower. Secondary endpoints were the number of desaturation episodes, the number of BIS episodes (defined as episodes of BIS value ≥ 61), PACU observation time, and PACU self-reported symptoms. Sample size justification With 50 patients per study arm, the precision for the bounds of a 2-sided 95% confidence interval (CI) for the ToLDE time would extend 0.39 min on each side of the observed mean, assuming a common standard deviation of 1.0 min per group. If the ToLDE time exhibited a highly skewed distribution, the proportion of patients experiencing at least one desaturation episode would be estimated for each study arm. Assuming a 15% desaturation rate and n = 50 patients, the half-width of a 2-sided 95% CI would extend approximately 10% points on each side of the expected proportion (nQuery Advisor, v. 7.0). Patient enrollment A designated study faculty member screened all patients scheduled for total intravenous anesthesia procedures for interventional radiology procedures between November 2019 and July 2023 at The University of Texas MD Anderson Cancer Center. Eligible participants included patients with a diagnosis of obstructive sleep apnea (OSA), regardless of home use of continuous positive airway pressure therapy. In addition, patients without a formal OSA diagnosis were considered eligible if they had a body mass index (BMI) ≥ 32 kg/m2 and a neck circumference ≥ 40 cm, as these features are associated with increased risk of airway obstruction. Exclusion criteria included age ≤ 18 years; severe organ system decompensation precluding tolerance of deep sedation; active pulmonary disease requiring supplemental oxygen; significantly compromised airways due to aerodigestive malignancy or mass effect, for which minimal sedation or awake airway intubation would be more appropriate; or a baseline oxygen saturation (SpO2) ≤ 92%. Data collection Data collected included patient demographics, American Society of Anesthesiologists (ASA) physical status classification, Mallampati score, frequency and duration of oxygen desaturation events, frequency and duration of BIS excursions, and patient-reported symptoms in the PACU. To minimize artifacts commonly encountered in electronic anesthesia records, particularly those related to patient movement or airway interventions, study personnel manually recorded desaturation events and BIS excursions in real time. PACU patient-reported symptoms were assessed using a standardized checklist and recorded either at the time patients met institutional discharge criteria or within 30 min of their PACU admission. Statistical analyses Descriptive statistics were used to summarize patient characteristics and study outcomes. Distributional properties and relationships between variables were explored using graphical methods, including scatterplots. For continuous outcomes, such as total length of desaturation episodes (ToLDE), 2-sided 95% confidence intervals (CIs) were calculated for each study arm. Between-group comparisons were conducted using the Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for categorical variables. Logistic regression analysis was performed to evaluate the association between treatment group and the occurrence of at least one desaturation episode, adjusting for relevant covariates. All analyses were conducted using Stata v. 16 (StataCorp), with a significance threshold of P < 0.05. Results Patient characteristics A total of 114 patients were identified as eligible for participation; 6 declined enrollment, and 108 patients were randomized to the study arms. Of these, 6 patients were excluded prior to the procedure due to last-minute procedural changes, and one patient was excluded due to a change in the anesthesia plan by the patient that precluded data collection. Thus, 101 patients were included in the final analysis: 50 patients in the HFNO group and 51 patients in the SoC group (Fig. 1). Baseline patient characteristics are summarized in Table 1, while airway-related variables and relevant comorbidities are presented in Table 2. Fig. 1CONSORT Diagram. HFNO, high-flow nasal oxygen CONSORT Diagram. HFNO, high-flow nasal oxygen Table 1Patient Characteristics by Study ArmHFNO (N = 50)SoC (N = 51)Total (N = 101)Age, years Mean (SD)60.18 (11.96)60.96 (11.97)60.57 (11.91) Median (IQR)62 (50.75–70.00)64 (54.00–68.00)63 (51.50–69.00) Range34.00–83.0031.00–82.0031.00–83.00BMIa, kg/m2 Mean (SD)37.02 (5.84)39.46 (7.96)38.26 (7.07) Median (IQR)35.99 (33.60–40.09)38.08 (34.72–45.51)37.33 (33.74–43.48) Range22.35–52.0724.92–67.0522.35–67.05Heighta, cm Mean (SD)170.99 (11.45)168.96 (9.76)169.96 (10.62) Median (IQR)169 (163.00–179.35)169 (162.00–176.00)169 (162.70–176.38) Range147.00–192.00145.00–188.00145.00–192.00Weightb, kg Mean (SD)107.12 (22.81)109.36 (21.6)108.24 (22.12) Median (IQR)110.6 (95.50–117.20)108.5 (95.50–120.10)109.25 (95.50–118.50) Range36.40–162.0062.40–159.9036.40–162.00Sex, n (%) Female22 (44)23 (45)45 (45) Male28 (56)28 (55)56 (55)ASA statusc, n (%) II1 (2)2 (4)3 (3) III49 (98)48 (96)97 (97)Mallampati scorec, n (%) I1 (2)1 (2)2 (2) II14 (28)17 (34)31 (31) III33 (66)32 (64)65 (65) IV2 (4)0 (0)2 (2)Abbreviations: ASA American Society of Anesthesiologists, BMI body mass index, IQR interquartile range, HFNO high-flow nasal oxygen, SD standard deviation, SoC standard of carea Missing data for 1 patient in the HFNO groupb Missing data for 3 patients in the HFNO group and 4 patients in the SoC groupc Missing data for 1 patient in the SoC group Table 1Patient Characteristics by Study ArmHFNO (N = 50)SoC (N = 51)Total (N = 101)Age, years Mean (SD)60.18 (11.96)60.96 (11.97)60.57 (11.91) Median (IQR)62 (50.75–70.00)64 (54.00–68.00)63 (51.50–69.00) Range34.00–83.0031.00–82.0031.00–83.00BMIa, kg/m2 Mean (SD)37.02 (5.84)39.46 (7.96)38.26 (7.07) Median (IQR)35.99 (33.60–40.09)38.08 (34.72–45.51)37.33 (33.74–43.48) Range22.35–52.0724.92–67.0522.35–67.05Heighta, cm Mean (SD)170.99 (11.45)168.96 (9.76)169.96 (10.62) Median (IQR)169 (163.00–179.35)169 (162.00–176.00)169 (162.70–176.38) Range147.00–192.00145.00–188.00145.00–192.00Weightb, kg Mean (SD)107.12 (22.81)109.36 (21.6)108.24 (22.12) Median (IQR)110.6 (95.50–117.20)108.5 (95.50–120.10)109.25 (95.50–118.50) Range36.40–162.0062.40–159.9036.40–162.00Sex, n (%) Female22 (44)23 (45)45 (45) Male28 (56)28 (55)56 (55)ASA statusc, n (%) II1 (2)2 (4)3 (3) III49 (98)48 (96)97 (97)Mallampati scorec, n (%) I1 (2)1 (2)2 (2) II14 (28)17 (34)31 (31) III33 (66)32 (64)65 (65) IV2 (4)0 (0)2 (2)Abbreviations: ASA American Society of Anesthesiologists, BMI body mass index, IQR interquartile range, HFNO high-flow nasal oxygen, SD standard deviation, SoC standard of carea Missing data for 1 patient in the HFNO groupb Missing data for 3 patients in the HFNO group and 4 patients in the SoC groupc Missing data for 1 patient in the SoC group Patient Characteristics by Study Arm Abbreviations: ASA American Society of Anesthesiologists, BMI body mass index, IQR interquartile range, HFNO high-flow nasal oxygen, SD standard deviation, SoC standard of care a Missing data for 1 patient in the HFNO group b Missing data for 3 patients in the HFNO group and 4 patients in the SoC group c Missing data for 1 patient in the SoC group Table 2Clinical measurements and history of comorbidities by study armHFNO (N = 50)SoC (N = 51) P Total (N = 101)Clinical measurements Neck circumference, cm Mean (SD)43.46 (5.39)43.78 (4.5)43.62 (4.94) Median (IQR)42 (39.88–46.25)43.5 (40.00–47.00)0.514a43 (40.00–47.00) Range35.00–58.0035.00–56.0035.00–58.00 Inter-incisor gap distance, cm Mean (SD)5.62 (1.24)5.76 (1.32)5.69 (1.28) Median (IQR)6 (4.88–6.50)6 (4.50–7.00)0.628a6 (4.50–6.50) Range3.20–10.003.50–9.003.20–10.00 Thyromental distance, cm Mean (SD)8.16 (1.88)8.03 (1.9)8.1 (1.88) Median (IQR)8 (7.00–9.62)8 (6.50–9.00)0.669a8 (7.00–9.00) Range4.00–12.005.00–14.004.00–14.00 Sternomental distance, cm Mean (SD)13.01 (2.32)12.6 (1.91)12.8 (2.12) Median (IQR)13 (11.38–14.50)12 (11.00–14.00)0.303a13 (11.00–14.00) Range7.00–18.009.00–18.007.00–18.00Comorbidities History of snoring, n (%) No21 (42)16 (31)0.306b37 (37) Yes29 (58)35 (69)64 (63) History of DMV, n (%) No50 (100)51 (100)----c101 (100) OSA, n (%) No22 (44)18 (35)0.419b40 (40) Yes28 (56)33 (65)61 (60) BMI > 35 kg/m2, n (%) No25 (50)18 (35)0.161b43 (43) Yes25 (50)33 (65)58 (57) Anterior DMV, n (%) No50 (100)51 (100)----c101 (100) Age > 55 years, n (%) No22 (44)18 (35)0.419b40 (40) Yes28 (56)33 (64)61 (60) Edentulousness, n (%) No35 (70)39 (76)0.506b74 (73) Yes15 (30)12 (24)27 (27)Abbreviations: BMI body mass index, DMV difficult mask ventilation, IQR interquartile range, HFNO high-flow nasal oxygen, OSA obstructive sleep apnea, SD standard deviation, SoC standard of careaWilcoxon rank-sum test P valuebFisher’s exact test P valueCNo statistical comparison Table 2Clinical measurements and history of comorbidities by study armHFNO (N = 50)SoC (N = 51) P Total (N = 101)Clinical measurements Neck circumference, cm Mean (SD)43.46 (5.39)43.78 (4.5)43.62 (4.94) Median (IQR)42 (39.88–46.25)43.5 (40.00–47.00)0.514a43 (40.00–47.00) Range35.00–58.0035.00–56.0035.00–58.00 Inter-incisor gap distance, cm Mean (SD)5.62 (1.24)5.76 (1.32)5.69 (1.28) Median (IQR)6 (4.88–6.50)6 (4.50–7.00)0.628a6 (4.50–6.50) Range3.20–10.003.50–9.003.20–10.00 Thyromental distance, cm Mean (SD)8.16 (1.88)8.03 (1.9)8.1 (1.88) Median (IQR)8 (7.00–9.62)8 (6.50–9.00)0.669a8 (7.00–9.00) Range4.00–12.005.00–14.004.00–14.00 Sternomental distance, cm Mean (SD)13.01 (2.32)12.6 (1.91)12.8 (2.12) Median (IQR)13 (11.38–14.50)12 (11.00–14.00)0.303a13 (11.00–14.00) Range7.00–18.009.00–18.007.00–18.00Comorbidities History of snoring, n (%) No21 (42)16 (31)0.306b37 (37) Yes29 (58)35 (69)64 (63) History of DMV, n (%) No50 (100)51 (100)----c101 (100) OSA, n (%) No22 (44)18 (35)0.419b40 (40) Yes28 (56)33 (65)61 (60) BMI > 35 kg/m2, n (%) No25 (50)18 (35)0.161b43 (43) Yes25 (50)33 (65)58 (57) Anterior DMV, n (%) No50 (100)51 (100)----c101 (100) Age > 55 years, n (%) No22 (44)18 (35)0.419b40 (40) Yes28 (56)33 (64)61 (60) Edentulousness, n (%) No35 (70)39 (76)0.506b74 (73) Yes15 (30)12 (24)27 (27)Abbreviations: BMI body mass index, DMV difficult mask ventilation, IQR interquartile range, HFNO high-flow nasal oxygen, OSA obstructive sleep apnea, SD standard deviation, SoC standard of careaWilcoxon rank-sum test P valuebFisher’s exact test P valueCNo statistical comparison Clinical measurements and history of comorbidities by study arm Abbreviations: BMI body mass index, DMV difficult mask ventilation, IQR interquartile range, HFNO high-flow nasal oxygen, OSA obstructive sleep apnea, SD standard deviation, SoC standard of care aWilcoxon rank-sum test P value bFisher’s exact test P value CNo statistical comparison TOLDE and number of desaturation episodes The mean ToLDE time in the HFNO group was 0.34 min (95%CI: 0.01–0.67; median, 0 min; range, 0–6.5 min), and the mean ToLDE in the SoC group was 0.97 min (95%CI: 0.05–1.88; median, 0 min; range: 0–19.8 min; P = 0.158; Table 3). The distribution of ToLDE time was highly skewed because most patients (80%) failed to experience desaturation episodes. Table 3ToLDE time, Length of PACU Observation, and BIS Episodes by Study ArmHFNO (N = 50)SoC (N = 51) P Total (N = 101)ToLDE time, mins Mean (SD)0.34 (1.16)0.97 (3.25)0.66 (2.46) Median (IQR)0 (0.00–0.00)0 (0.00–0.02)0.158a0 (0.00–0.00) Range0.00–6.500.00–19.780.00–19.78Total SpO2 ≤92% episodes, n (%) 043 (86)38 (75)0.514b81 (80) 13 (6)4 (8)7 (7) 22 (4)4 (8)6 (6) 3 or more2 (4)5 (10)7 (7)Experienced at least 1 SpO2 ≤92% episode, n (%) No43 (86)38 (74)0.212b81 (80) Yes7 (14)13 (26)20 (20)Min SpO2c, %n = 7n = 13N = 20 Mean (SD)90 (2.83)88.62 (3.91)89.1 (3.55) Median (IQR)91 (87.00–92.00)90 (84.00–92.00)0.349a91 (85.50–92.00) Range85.00–92.0081.00–92.0081.00–92.00Max SpO2c, %n = 7n = 13N = 20 Mean (SD)91.86 (0.38)90.38 (2.93)90.9 (2.45) Median (IQR)92 (92.00–92.00)92 (90.00–92.00)0.203a92 (91.00–92.00) Range91.00–92.0084.00–92.0084.00–92.00Length of PACU observationd, min Mean (SD)24.62 (17.87)30.39 (16.25)27.53 (17.23) Median (IQR)20 (12.25–39.00)26 (18.00–44.00)0.076a23 (14.00–41.00) Range0.00–60.005.00–60.000.00–60.00Total BIS value ≥61 episodes Mean (SD)3 (3.1)4.69 (3.75)3.85 (3.53) Median (IQR)2 (1.00–4.25)4 (2.00–6.00)0.005a3 (1.00–5.00) Range0.00–15.000.00–19.000.00–19.00Experienced at least one BIS≥61 episode, n (%) No10 (20)5 (10)0.172b15 (15) Yes40 (80)46 (90)86 (85)Abbreviations: BIS bispectral index, HFNO high-flow nasal oxygen, IQR interquartile range, Max maximum, Min minimum, PACU post-anesthesia care unit, SD standard deviation, SoC standard of care, SpO2 oxygen saturation, ToLDE total length of desaturation episodea Wilcoxon rank-sum test P valueb Fisher’s exact test P valuec Of patients who experienced a desaturation episoded Missing data for 1 patient in the SoC group Table 3ToLDE time, Length of PACU Observation, and BIS Episodes by Study ArmHFNO (N = 50)SoC (N = 51) P Total (N = 101)ToLDE time, mins Mean (SD)0.34 (1.16)0.97 (3.25)0.66 (2.46) Median (IQR)0 (0.00–0.00)0 (0.00–0.02)0.158a0 (0.00–0.00) Range0.00–6.500.00–19.780.00–19.78Total SpO2 ≤92% episodes, n (%) 043 (86)38 (75)0.514b81 (80) 13 (6)4 (8)7 (7) 22 (4)4 (8)6 (6) 3 or more2 (4)5 (10)7 (7)Experienced at least 1 SpO2 ≤92% episode, n (%) No43 (86)38 (74)0.212b81 (80) Yes7 (14)13 (26)20 (20)Min SpO2c, %n = 7n = 13N = 20 Mean (SD)90 (2.83)88.62 (3.91)89.1 (3.55) Median (IQR)91 (87.00–92.00)90 (84.00–92.00)0.349a91 (85.50–92.00) Range85.00–92.0081.00–92.0081.00–92.00Max SpO2c, %n = 7n = 13N = 20 Mean (SD)91.86 (0.38)90.38 (2.93)90.9 (2.45) Median (IQR)92 (92.00–92.00)92 (90.00–92.00)0.203a92 (91.00–92.00) Range91.00–92.0084.00–92.0084.00–92.00Length of PACU observationd, min Mean (SD)24.62 (17.87)30.39 (16.25)27.53 (17.23) Median (IQR)20 (12.25–39.00)26 (18.00–44.00)0.076a23 (14.00–41.00) Range0.00–60.005.00–60.000.00–60.00Total BIS value ≥61 episodes Mean (SD)3 (3.1)4.69 (3.75)3.85 (3.53) Median (IQR)2 (1.00–4.25)4 (2.00–6.00)0.005a3 (1.00–5.00) Range0.00–15.000.00–19.000.00–19.00Experienced at least one BIS≥61 episode, n (%) No10 (20)5 (10)0.172b15 (15) Yes40 (80)46 (90)86 (85)Abbreviations: BIS bispectral index, HFNO high-flow nasal oxygen, IQR interquartile range, Max maximum, Min minimum, PACU post-anesthesia care unit, SD standard deviation, SoC standard of care, SpO2 oxygen saturation, ToLDE total length of desaturation episodea Wilcoxon rank-sum test P valueb Fisher’s exact test P valuec Of patients who experienced a desaturation episoded Missing data for 1 patient in the SoC group ToLDE time, Length of PACU Observation, and BIS Episodes by Study Arm Abbreviations: BIS bispectral index, HFNO high-flow nasal oxygen, IQR interquartile range, Max maximum, Min minimum, PACU post-anesthesia care unit, SD standard deviation, SoC standard of care, SpO2 oxygen saturation, ToLDE total length of desaturation episode a Wilcoxon rank-sum test P value b Fisher’s exact test P value c Of patients who experienced a desaturation episode d Missing data for 1 patient in the SoC group Of all 101 patients, 20 (20%) experienced at least one desaturation episode. In the HFNO group, 7 patients (14%; 95% CI, 6%–27%) experienced at least one desaturation episode, and in the SoC group, 13 patients (26%; 95% CI, 14%–40%) experienced at least one desaturation episode (P = 0.212). Among the 20 patients experiencing desaturation episodes, ToLDE time ranged from approximately 1 s to 19.8 min (Table 3). Among the patients who experienced desaturation episodes, the mean ToLDE time was similar in the HFNO group (2.44 min; 95% CI, 0.36–4.52 min) and in the SoC group (3.79 min; 95% CI, 0.35–7.23 min). BIS episodes and PACU observation time The median number of BIS excursions (≥ 61) was significantly higher for patients in the SoC group (4; range, 0–19) than for patients in the HFNO group (2; range, 0–15; P = 0.005; Table 3; Fig. 2). The median PACU length of stay was longer for patients in the SoC group (26 min; range, 5–60 min) than patients in the HFNO group (20 min; range, 0–60 min, although this difference did not reach statistical significance (P = 0.076; Fig. 3). Fig. 2Total Number of Episodes (Bispectral Index [BIS] Value ≥ 61) by Study Arm. HFNO, high-flow nasal oxygen Total Number of Episodes (Bispectral Index [BIS] Value ≥ 61) by Study Arm. HFNO, high-flow nasal oxygen Fig. 3Post-Anesthesia Care Unit Observation Time by Study Arm. HFNO, high-flow nasal oxygen Post-Anesthesia Care Unit Observation Time by Study Arm. HFNO, high-flow nasal oxygen PACU self-reported symptoms Patients reported symptoms including jaw pain, sore tongue, and dysphagia. In the SoC group, 8 patients (16%) reported symptoms: jaw pain (n = 2; severe), sore tongue (n = 2; moderate), and dysphagia (n = 4; mild). In the HFNO group, 6 patients (12%) reported symptoms: sore tongue (n = 4; mild) and dysphagia (n = 2; mild). No patients in the HFNO group reported jaw pain. The overall proportion of patients reporting symptoms did not differ significantly between groups (P = 0.592), although symptoms severity appeared lower in the HFNO group (HFNO, 12%, vs. SoC, 16%). No cases of dysphonia were reported. Association between patient comorbidities and desaturation episodes Baseline prevalence of OSA and obesity was higher in the SoC group, although differences were not statistically significant (OSA: 56%, vs. 65%; P = 0.419; obesity: 50% vs. 65%; P = 0.161). OSA, obesity, and other comorbidities and clinical characteristics are summarized in Table 2. In univariable logistic regression, obesity was associated with a nonsignificant (14%) increase in the odds of desaturation (odds ratio [OR] = 1.14; 95% CI, 0.42–3.09; P = 0.795), whereas OSA was associated with a nonsignificant (24%) decrease (OR = 0.76; 95% CI, 0.28–2.04; P = 0.582). In multivariable analysis adjusting for obesity and OSA, HFNO was associated with a 54% reduction in the odds of desaturation compared with SoC (OR = 0.46; 95% CI, 0.16–1.30; P = 0.143), although this finding was not statistically significant. Discussion Although prior studies and meta-analyses have demonstrated that HFNO reduces the incidence and duration of hypoxic events in patients at risk of hypoxemia during deep sedation [4, 5], our study did not find a statistically significant benefit of HFNO over standard oxygen delivery in this high-risk population. Specifically, there were no significant differences in ToLDE or the incidence of desaturation between groups. These findings do not support our study hypothesis. A previous multicenter study of 379 participants found that HFNO significantly reduced the incidence of desaturation episodes (SpO2 ≤92%) by 23.4% (P < 0.001) in patients undergoing deep sedation for gastrointestinal endoscopies [5]. However, our study did not observe similar outcomes, which may be explained by differences in patient populations and procedural conditions. Our cohort consisted primarily of patients with increased risks of airway obstruction, whereas the previous study included patients with various systemic comorbidities related to respiration and circulation. In our study, the median body mass index was 37.3 kg/m2 (IQR, 33.7–43.5 kg/m2), compared with 27 kg/m2 (IQR, 23.9–30.5 kg/m2) in the previous study. Additionally, our patients underwent interventional radiology procedures in the supine position, in contrast to the 15- to 30-degree upper body elevation used during the gastrointestinal endoscopies in the previous study; the supine position likely exacerbated the risk of airway obstruction and respiratory complications. The combination of a supine position and sedation in obese patients not only increases the risk of upper airway obstruction and overall respiratory workload but also exacerbates the respiratory mechanism by reducing the functional residual capacity and increasing the closing capacity of the lungs. When the mouth is closed, HFNO provides approximately 1 cm H2O positive airway pressure per 10 L/min oxygen flow, reaching a maximum of 7 to 8 cm H2O at 70 L/min [6, 7], and is described as “dynamic, not set and not constant” [8]. However, maintaining a patent airway requires constant positive airway pressure above a critical level that varies between individuals [9]. In our study, 14% of patients in the HFNO group experienced desaturation episodes. This finding aligns with others from meta-analyses focused on obese patients [10–12], which suggests that although HFNO prolongs safe apnea, it does not significantly reduce hypoxic events. Another meta-analysis of 10 randomized controlled studies published between 2014 and 2021 (n = 564; body mass index, 33–52 kg/m2) demonstrated that use of HFNO prolonged safe apnea time but did not reduce hypoxic events [11]. Further, Bright et al. conducted a meta-analysis and reported that use of a high-flow nasal cannula was not superior to use of a regular face mask in reducing hypoxic events (OR = 0.49; 95% CI, 0.15–1.63; P = 0.24) [12]. Although our findings did not support our hypothesis, some observations were suggestive for further investigation. These observations included fewer episodes of a BIS value of ≥ 61 (P = 0.005), shorter PACU stays (P = 0.07), and fewer and less severe PACU patient-reported symptoms in the HFNO group compared with the SoC group. These findings suggest that HFNO may offer benefits beyond oxygenation alone, particularly in optimizing sedation quality and patient experience. Frequent episodes of BIS value ≥ 61 during total intravenous anesthesia typically indicate inadequate sedation levels, increasing the risk of awareness and intraoperative movement, and potentially decreasing the patients’ anesthesia satisfaction. Study limitations This single-center pilot study was limited by its modest sample size and lack of blinding. Manual data collection may have introduced measurement variability. Additionally, the inclusion of both obese and OSA patients introduces heterogeneity in underlying pathophysiology. The respiratory mechanisms of OSA and obesity are not the same, although airway obstruction is a primary feature in both conditions. For instance, the closing capacity and functional residual capacity are less affected in non-obese patients than in obese patients. Imbalances in these characteristics between groups may have influenced results. Finally, the primary endpoint (ToLDE) exhibited a zero-inflated distribution, limiting its sensitivity and potentially reducing the ability to detect meaningful differences between groups. Conclusions In this randomized pilot study, HFNO did not significantly reduce hypoxic events compared with a standard non-rebreather oxygen delivery device in preventing hypoxic episodes among patients with increased risk of airway obstruction during interventional radiology procedures. However, HFNO was associated with improved sedation stability and trends toward enhanced patient experience. Larger, adequately powered studies are needed to determine whether these observations translate into clinically meaningful benefits.